5 completed, 1 enrolling by invitation, 1 terminated. 4 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 3 | Completed 2, Enrolling by invitation 1 |
| Phase 1 | 2 | Completed 2 |
Follow Mp alpha1 receptor: new trials by email Literature Review of Mp alpha1 receptor trials Research Report on Mp alpha1 receptor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Alpha-1 MP - Alpha1-Antitrypsin Deficiency | Phase 1 / Phase 2 | Completed | Grifols Therapeutics LLC | 4 | 2016-07-29 | 2022-03-31 |
| Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency Alpha-1 MP - Alpha1-Antitrypsin Deficiency | Phase 1 / Phase 2 | Completed | Grifols Therapeutics LLC | 4 | 2016-07-29 | 2021-10-28 |
| Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency Alpha-1 MP - Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | Enrolling by invitation | Grifols Therapeutics LLC | 290 | 2016-07-01 | 2026-06-23 |
| Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP - Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 345 | 2014-04-01 | 2026-10-01 |
| Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo - Type 1 Diabetes Mellitus | Phase 2 | Terminated | Grifols Therapeutics LLC | 76 | 2014-03-01 | 2018-09-05 |
| Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg - Emphysema, Alpha 1-antitrypsin Deficiency (AATD) | Phase 2 | Completed | Grifols Therapeutics LLC | 30 | 2010-11-01 | 2013-05-20 |
| Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Alpha-1 MP, alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 24 | 2006-05-01 | 2014-09-09 |
alpha 1-Antitrypsin Deficiency (7) · Pulmonary Emphysema (3) · Diabetes Mellitus, Type 1 (1) · Emphysema (1)
United States (5) · Australia (2) · Canada (2) · Denmark (2) · Estonia (2) · Finland (2) · France (2) · Japan (2) · Moldova (2) · New Zealand (2) · Poland (2) · Russia (2) · Sweden (2) · Argentina (1) · Brazil (1)
Charlie Strange, MD (1) · Friedrich Kueppers, MD (1) · James Stocks, MD (1) · Kim Hanna, MSc (1) · Mark Brantly, MD (1) · Michael Campos, MD (1)
PMID 20920295, PMID 25727857, PMID 30416054, PMID 33244872, PMID 35970714